Skip to main content
. 2022 Oct 20;82(14):1453–1468. doi: 10.1007/s40265-022-01785-1

Fig. 2.

Fig. 2

Forest plot of unadjusted (blue) and adjusted (red) HRs (95% CIs) of key outcomes comparing new use of ICS therapy with macrolide monotherapy for bronchiectasis. Adjusted hazard ratios included propensity score decile, oral corticosteroid dose category, and non-tuberculous mycobacteria history. Reproduced from Hencke et al. [108] (free access). HRs hazard ratios, CIs confidence intervals, ICS inhaled corticosteroid